- Conditions
- Bladder Cancer
- Interventions
- Paclitaxel, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- sorafenib tosylate, gemcitabine hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lung Cancer
- Interventions
- carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 74
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Solid Tumors
- Interventions
- INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more
- Conditions
- Adult Solid Tumor
- Interventions
- RP-6306 (oral PKMYT1 inhibitor)
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
- Conditions
- Solid Tumor
- Interventions
- 5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cervical Cancer
- Interventions
- Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
- Conditions
- Endometrial Adenocarcinoma
- Interventions
- ACR-368, Gemcitabine, OncoSignature
- Drug · Diagnostic Test
- Lead sponsor
- Acrivon Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Interventions
- Folfirinox, Gemcitabine nab-Paclitaxel
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine, PEGPH20, Placebo
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • San Francisco, California • Indianapolis, Indiana + 5 more
- Conditions
- Metastatic HER2-Positive Breast Cancer
- Interventions
- Gemcitabine, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 2 more
- Conditions
- Unresectable Locally Advanced Pancreatic Carcinoma
- Interventions
- OncoSil™
- Device
- Lead sponsor
- OncoSil Medical Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 1 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Regorafenib, Gemcitabine Hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, tanespimycin, cisplatin, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 74
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 63 more
- Conditions
- Pancreatic Neoplasms, Adenocarcinoma
- Interventions
- Gemcitabine, Etanercept
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pancreatic Ductal Carcinoma
- Interventions
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
- Other · Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more